Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center, randomized, double-blind, active-control, 96 week, phase III trial of the efficacy and safety of clevudine compared with adefovir at weeks 48 and 96 in nucleoside treatment-naive patients with HBeAg positive chronic hepatitis due to hepatitis B virus

Next Previous
X
Search
Trial Profile

A multi-center, randomized, double-blind, active-control, 96 week, phase III trial of the efficacy and safety of clevudine compared with adefovir at weeks 48 and 96 in nucleoside treatment-naive patients with HBeAg positive chronic hepatitis due to hepatitis B virus

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 12 Apr 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Clevudine (Primary) ; Adefovir
  • Indications Hepatitis B
  • Focus Therapeutic Use
  • Acronyms QUASH-1
  • Sponsors Pharmasset

    • Most Recent Events

    • 08 Apr 2022 This trial has been completed in Spain (End Date: 09 Jun 2009), according to European Clinical Trials Database record.
    • 20 Apr 2009 Status changed from recruiting to discontinued, according to Pharmasset media release.
    • 08 Jul 2008 Pharmasset plans to submit the 48-week data to the FDA as the basis for clevudine marketing approval.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top